IHS Chemical Week

People & Business :: Companies

Lonza Signs Manufacturing Deal with U.S. Pharma Firm

12:16 AM MDT | October 21, 2009 | Deepti Ramesh

Lonza says it has signed an agreement with Alnara Pharmaceuticals (Cambridge, MA), a company that develops and commercializes protein therapeutics for the treatment of metabolic diseases, to manufacture Alnara’s lead product liprotamase - an oral, pancreatic enzyme replacement therapy (PERT) for patients with pancreatic insufficiency. Lonza will provide microbial fermentation, process optimization, technical and regulatory support, under the terms of the deal, and all related production will be conducted in Lonza’s FDA registered facility at...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa